Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression.
Methods:
We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments. Veterans either received intranasal esketamine or racemic parenteral ketamine (intravenous or intramuscular). The Revised Mystical Experience Questionnaire (MEQ-30) was administered following ketamine treatments to assess the occurrence of mystical experience. A linear mixed model was used to examine the association between MEQ-30 scores and several treatment-related variables including gender, age, treatment number, dose, comorbid post-traumatic stress disorder, and pretreatment depression rating scores (PHQ-9).
Results:
Complete mystical experience was reported in 17.02% of esketamine treatments and 18.19% of racemic ketamine treatments. In the esketamine group, a greater number of treatment sessions was associated with higher MEQ-30 scores (p = 0.05). In the racemic ketamine group, higher doses were associated with higher MEQ-30 scores (p = 0.002).
Discussion:
These findings suggest that ketamine can occasion mystical experiences in veterans with treatment-resistant depression. Future studies should further explore the mystical-type effects of ketamine as a potential contributor to its therapeutic effect in treatment-resistant depression.
Get full access to this article
View all access options for this article.
References
1.
HoodRW. The Construction and Preliminary Validation of a Measure of Reported Mystical Experience. 1975.
2.
YadenDB, NewbergA. The Varieties of Spiritual Experience: 21st Century Research and Perspectives. Oxford: New York; 2022.
3.
YadenDB, Le NguyenKD, KernML, et al.Of roots and fruits: A comparison of psychedelic and nonpsychedelic mystical experiences. J Humanist Psychol, 2017; 57(4):338–353; doi: 10.1177/0022167816674625
GoldbergSB, ShechetB, NicholasCR, et al.Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis. Psychol Med, 2020; 50(16):2655–2666; doi: 10.1017/S003329172000389X
6.
GriffithsRR, HurwitzES, DavisAK, et al.Survey of Subjective “God Encounter Experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, Ayahuasca, or DMT. PLoS One, 2019; 14(4):e0214377; doi: 10.1371/journal.pone.0214377
7.
GriffithsRR, RichardsWA, JohnsonMW, et al.Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol, 2008; 22(6):621–632; doi: 10.1177/0269881108094300
8.
YadenDB, GriffithsRR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 2021; 4(2):568–572; doi: 10.1021/acsptsci.0c00194
9.
GriffithsRR, JohnsonMW, RichardsWA, et al.Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol, 2018; 32(1):49–69; doi: 10.1177/0269881117731279
10.
MurphyR, KettnerH, ZeifmanR, et al.Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol, 2021; 12:788155; doi: 10.3389/fphar.2021.788155
11.
ZeifmanRJ, WagnerAC, MonsonCM, et al.How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. J Affect Disord, 2023; 334:100–112; doi: 10.1016/j.jad.2023.04.105
12.
RosemanL, NuttDJ, Carhart-HarrisRL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol, 2017; 8(JAN):974; doi: 10.3389/fphar.2017.00974
13.
OlsonDE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 2021; 4(2):563–567; doi: 10.1021/acsptsci.0c00192
14.
HashimotoK. Are “Mystical Experiences” Essential for antidepressant actions of ketamine and the classic psychedelics? Eur Arch Psychiatry Clin Neurosci, 2024; doi: 10.1007/s00406-024-01770-7
15.
DenommeN, HeifetsBD. Ketamine, the first associative anesthetic? some considerations on classifying psychedelics, entactogens, and dissociatives. Am J Psychiatry, 2024; 181(9):784–786; doi: 10.1176/appi.ajp.20240644
16.
ZanosP, GouldTD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry, 2018; 23(4):801–811; doi: 10.1038/mp.2017.255
17.
LeGH, WongS, BadulescuS, et al.Spectral signatures of psilocybin, Lysergic Acid Diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. J Affect Disord, 2024; 355:342–354; doi: 10.1016/j.jad.2024.03.165
18.
DavoudianPA, ShaoLX, KwanAC. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci, 2023; 14(3):468–480; doi: 10.1021/acschemneuro.2c00637
19.
DaiR, LarkinTE, HuangZ, et al.Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage, 2023; 273:120097; doi: 10.1016/j.neuroimage.2023.120097
20.
CurranHV, MorganC. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction, 2000; 95(4):575–590; doi: 10.1046/j.1360-0443.2000.9545759.x
21.
HessEM, GreensteinDK, HutchinsonOL, et al.Entactogen effects of ketamine: A reverse-translational study. AJP, 2024; 181(9):815–823; doi: 10.1176/appi.ajp.20230980
22.
MollaahmetogluOM, KeelerJ, AshbullbyKJ, et al.“This Is Something That Changed My Life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry, 2021; 12:695335; doi: 10.3389/fpsyt.2021.695335
23.
RobisonR, BrendleM, MooreC, et al.Ketamine-assisted group psychotherapy for frontline healthcare workers with COVID-19-Related burnout and PTSD: A case series of effectiveness/safety for 10 participants. J Psychoactive Drugs, 2024; 56(1):23–32; doi: 10.1080/02791072.2023.2186285
24.
CastilloA, DuboisJ, FieldRM, et al.Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS. Sci Rep, 2023; 13(1):11665; doi: 10.1038/s41598-023-38258-8
25.
RothbergRL, AzhariN, HaugNA, et al.Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol, 2021; 35(2):150–158; doi: 10.1177/0269881120970879
26.
DakwarE, NunesEV, HartCL, et al.A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 2018; 142:270–276; doi: 10.1016/j.neuropharm.2018.01.005
27.
AepfelbacherJ, PannyB, PriceRB. Experiences of awe mediate ketamine’s antidepressant effects: Findings from a randomized controlled trial in treatment-resistant depression. Biol Psychiatry Glob Open Sci, 2024; 4(4):100316; doi: 10.1016/j.bpsgos.2024.100316
28.
BarrettFS, JohnsonMW, GriffithsRR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol, 2015; 29(11):1182–1190; doi: 10.1177/0269881115609019
29.
StuderusE, GammaA, KometerM, et al.Prediction of psilocybin response in healthy volunteers. PLoS One, 2012; 7(2):e30800; doi: 10.1371/journal.pone.0030800
30.
KoK, CarterB, CleareAJ, et al.Predicting the intensity of psychedelic-induced mystical and challenging experience in a healthy population: An exploratory post-hoc analysis. Neuropsychiatr Dis Treat, 2023; 19:2105–2113; doi: 10.2147/NDT.S426193
31.
VizeliP, StuderusE, HolzeF, et al.Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants. Transl Psychiatry, 2024; 14(1):357; doi: 10.1038/s41398-024-03074-9
32.
GriffithsRR, JohnsonMW, RichardsWA, et al.Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl), 2011; 218(4):649–665; doi: 10.1007/s00213-011-2358-5
33.
MathaiDS, HilbertS, SepedaND, et al.Double-blind comparison of the two hallucinogens dextromethorphan and psilocybin: Experience-dependent and enduring psychological effects in healthy volunteers. Psychedelic Med (New Rochelle), 2023; 1(4):241–252; doi: 10.1089/psymed.2023.0035
34.
CarbonaroTM, JohnsonMW, HurwitzE, et al.Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences. Psychopharmacology (Berl), 2018; 235(2):521–534; doi: 10.1007/s00213-017-4769-4
35.
NichterB, NormanS, HallerM, et al.Psychological burden of PTSD, depression, and their comorbidity in the U.S. veteran population: Suicidality, functioning, and service utilization. J Affect Disord, 2019; 256:633–640; doi: 10.1016/j.jad.2019.06.072
36.
JohnsonMW, RichardsWA, GriffithsRR. Human Hallucinogen research: Guidelines for safety. J Psychopharmacol, 2008; 22(6):603–620; doi: 10.1177/0269881108093587
37.
PhamTH, Mendez-DavidI, DefaixC, et al.Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology, 2017; 112(Pt A):198–209; doi: 10.1016/j.neuropharm.2016.05.010
38.
HalberstadtAL, GeyerMA. Multiple receptors contribute to the behavioral effects of Indoleamine Hallucinogens. Neuropharmacology, 2011; 61(3):364–381; doi: 10.1016/j.neuropharm.2011.01.017
39.
Perez-RuixoC, RossenuS, ZannikosP, et al.Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression. Clin Pharmacokinet, 2021; 60(4):501–516; doi: 10.1007/s40262-020-00953-4
40.
HaijenECHM, KaelenM, RosemanL, et al.Predicting responses to psychedelics: A prospective study. Front Pharmacol, 2018; 9(NOV):897; doi: 10.3389/fphar.2018.00897
41.
RussSL, Carhart-HarrisRL, MaruyamaG, et al.Replication and extension of a model predicting response to psilocybin. Psychopharmacology (Berl), 2019; 236(11):3221–3230; doi: 10.1007/s00213-019-05279-z
42.
LevinAW, LancelottaR, SepedaND, et al.The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS One, 2024; 19(3):e0300501; doi: 10.1371/journal.pone.0300501
43.
AustS, GärtnerM, BassoL, et al.Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol, 2019; 29(4):529–538; doi: 10.1016/j.euroneuro.2019.02.005
44.
GriffithsC, WalkerK, ReidI, et al.A qualitative study of patients’ experience of ketamine treatment for depression: The ‘Ketamine and me’ project. J Affect Disord Rep, 2021; 4; doi: 10.1016/j.jadr.2021.100079
45.
FavaM, FreemanMP, FlynnM, et al.Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry, 2020; 25(7):1592–1603; doi: 10.1038/s41380-018-0256-5
46.
GlueP, NeehoffS, BeagleholeB, et al.Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. J Psychopharmacol, 2024; 38(2):162–167; doi: 10.1177/02698811241227026
47.
HirschfeldT, PruggerJ, MajićT, et al.Dose-response relationships of LSD-induced subjective experiences in humans. Neuropsychopharmacology, 2023; 48(11):1602–1611; doi: 10.1038/s41386-023-01588-2
48.
HirschfeldT, SchmidtTT. Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol, 2021; 35(4):384–397; doi: 10.1177/0269881121992676
49.
MathaiDS, MeyerMJ, StorchEA, et al.The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord, 2020; 264:123–129; doi: 10.1016/j.jad.2019.12.023
50.
KaelenM, GiribaldiB, RaineJ, et al.The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl), 2018; 235(2):505–519; doi: 10.1007/s00213-017-4820-5
51.
MetznerR. Hallucinogenic drugs and plants in psychotherapy and shamanism. J Psychoactive Drugs, 1998; 30(4):333–341; doi: 10.1080/02791072.1998.10399709
52.
GandyS. Predictors and potentiators of psychedelic-occasioned mystical experiences. J Psychedelic Stud, 2022; 6(1):31–47; doi: 10.1556/2054.2022.00198
53.
SmigielskiL, KometerM, ScheideggerM, et al.Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep, 2019; 9(1):14914; doi: 10.1038/s41598-019-50612-3
54.
SabéM, SulstarovaA, GlangetasA, et al.Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry, 2025; 30(3):1223–1255; doi: 10.1038/s41380-024-02800-5
55.
MathaiDS, MoraV, Garcia-RomeuA. Toward synergies of ketamine and psychotherapy. Front Psychol, 2022; 13:868103; doi: 10.3389/fpsyg.2022.868103
56.
GarelN, DruryJ, Thibault LévesqueJ, et al.The Montreal model: An integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry, 2023; 14:1268832; doi: 10.3389/fpsyt.2023.1268832
